

# Justin A Ezekowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3700036/publications.pdf>

Version: 2024-02-01

361  
papers

35,811  
citations

10986

71  
h-index

3732

179  
g-index

370  
all docs

370  
docs citations

370  
times ranked

27996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 130-139.	3.0	24
2	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. <i>CJC Open</i> , 2022, 4, 180-188.	1.5	2
3	The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada. <i>Journal of Cardiac Failure</i> , 2022, 28, 237-246.	1.7	5
4	Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 195-201.	4.0	5
5	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
6	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	8.6	25
7	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2022, 4, e46-e54.	12.3	62
8	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. <i>Contemporary Clinical Trials</i> , 2022, 113, 106646.	1.8	3
9	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	7.1	820
10	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	1.7	23
11	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. <i>ESC Heart Failure</i> , 2022, 9, 1564-1573.	3.1	3
12	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
13	Fluid Restriction: Time to Let it Flow?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1480-1481.	1.7	3
14	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 1391-1400.	13.7	67
15	Nationwide study of sex differences in incident heart failure in newly diagnosed nonvalvular atrial fibrillation. <i>CJC Open</i> , 2022, , .	1.5	0
16	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	3.1	1
17	Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat. <i>Journal of Cardiac Failure</i> , 2022, 28, 1298-1308.	1.7	8
18	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e024833.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	10
20	Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada. <i>Scientific Reports</i> , 2022, 12, .	3.3	8
21	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 220-228.	1.2	10
22	Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. <i>CJC Open</i> , 2021, 3, 361-366.	1.5	5
23	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	1.7	4
24	Evidence-Based Management of Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2021, 37, 621-631.	1.7	16
25	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	1.7	170
26	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. <i>Journal of Cardiac Failure</i> , 2021, 27, 602-606.	1.7	13
27	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	3.7	6
28	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	3.9	30
29	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	4.1	23
30	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
31	Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 13.	2.0	8
32	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 497-505.	4.1	5
33	Cost-Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation. <i>Journal of the American Heart Association</i> , 2021, 10, e019599.	3.7	13
34	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the <sc>PACT-HF</sc> randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1488-1498.	7.1	22
35	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	3.9	32
36	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21

#	ARTICLE	IF	CITATIONS
37	Residuals. Circulation, 2021, 144, 438-440.	1.6	1
38	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	3.9	12
39	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
40	Impact of Atrial Fibrillation Case Volume in the Emergency Department on Early and Late Outcomes of Patients With New Atrial Fibrillation. Annals of Emergency Medicine, 2021, 78, 242-252.	0.6	3
41	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. Current Heart Failure Reports, 2021, 18, 253-263.	3.3	6
42	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). American Journal of Cardiology, 2021, 154, 123-126.	1.6	1
43	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. Journal of Cardiac Failure, 2021, 27, 934-941.	1.7	0
44	Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 5352-5362.	3.1	12
45	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	1.7	8
46	Chloride in Heart Failure. JACC: Heart Failure, 2021, 9, 904-915.	4.1	22
47	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. Journal of the American Heart Association, 2021, 10, e021094.	3.7	23
48	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Failure, 2021, , .	3.1	3
49	Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 45-58.	1.0	14
50	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. Canadian Journal of Diabetes, 2020, 44, 103-110.	0.8	2
51	Management of Comorbidities in Heart Failure. , 2020, , 687-696.e2.		0
52	All for one, but not one for all. European Heart Journal, 2020, 41, 642-644.	2.2	1
53	OUTSMART HF. Circulation, 2020, 141, 818-827.	1.6	19
54	Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study. CJC Open, 2020, 2, 8-14.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department. <i>Europace</i> , 2020, 22, 695-703.	1.7	22
56	Eligibility of sodium-glucose cotransporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. <i>ESC Heart Failure</i> , 2020, 7, 275-279.	3.1	6
57	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	4.1	88
58	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.4	170
59	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
60	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 81.	3.3	21
61	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020, 74, e13625.	1.7	5
62	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017278.	3.7	23
63	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	3.7	2
64	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. <i>Circulation: Heart Failure</i> , 2020, 13, e006952.	3.9	4
65	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1148-1151.	1.7	19
66	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
67	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	2.7	24
68	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	2.2	47
69	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	1.5	10
70	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	7.1	27
71	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	27.0	753
72	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	3.1	7

#	ARTICLE	IF	CITATIONS
73	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2020, 317, 167-173.	1.7	25
74	Underrepresentation of Women in Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2020, 36, 969.e7-969.e8.	1.7	5
75	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	2.4	5
76	Substance and Substrate. <i>Circulation</i> , 2020, 141, 362-366.	1.6	16
77	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	1.7	89
78	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
79	Elevated Blood Pressure and Associations with Sodium Intake Among Multiethnic Youth in Edmonton, Canada: Findings from WHY ACT NOW. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 239-249.	2.2	3
80	The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure. <i>Frontiers in Physiology</i> , 2020, 11, 195.	2.8	4
81	Press 1 to Speak to a Representative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007297.	2.2	0
82	Is incentivising stroke prevention therapy in atrial fibrillation the key?. <i>Heart</i> , 2019, 105, 4-5.	2.9	1
83	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019, 152, 301-316.	0.8	1
84	Screening and Initiating Supportive Care in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 151.	2.4	5
85	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2511-2524.	2.8	54
86	Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades. <i>JAMA Cardiology</i> , 2019, 4, 1122.	6.1	32
87	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1205-1217.	2.8	54
88	Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 58.	3.3	14
89	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics. <i>CJC Open</i> , 2019, 1, 173-181.	1.5	2
90	Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1412-1415.	1.7	12

#	ARTICLE	IF	CITATIONS
91	Creating order out of chaos: quality of care in heart failure. <i>Heart</i> , 2019, 105, 429-430.	2.9	2
92	The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement. <i>Canadian Journal of Cardiology</i> , 2019, 35, 413-421.	1.7	11
93	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	3.9	33
94	External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department. <i>CJC Open</i> , 2019, 1, 123-130.	1.5	7
95	External Validation of the H <sub>2</sub> F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2019, 139, 2377-2379.	1.6	44
96	High vs. low oxygen therapy in patients with acute heart failure: <sc>HiLoâ€HF</sc> pilot trial. <i>ESC Heart Failure</i> , 2019, 6, 667-677.	3.1	16
97	Incremental costs of high intensive care utilisation in patients hospitalised with heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 660-666.	1.0	4
98	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019, 40, 2110-2117.	2.2	63
99	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€T predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	7.1	36
100	Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 710-718.	0.6	12
101	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 904.	4.1	116
102	Update on the diagnosis and management of acute heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 202-206.	1.8	6
103	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
104	Heart failure treatment and the art of medical decision making. <i>European Journal of Heart Failure</i> , 2019, 21, 1510-1514.	7.1	5
105	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 149-154.	1.9	14
106	NT-proBNP Goal Achievement Isâ€Associated With Significant Reverseâ€Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	4.1	65
107	Frailty modelling for multitype recurrent events in clinical trials. <i>Statistical Modelling</i> , 2019, 19, 140-156.	1.1	4
108	Insights on the Use of Twitter at the Canadian Cardiovascular Congress. <i>Canadian Journal of Cardiology</i> , 2018, 34, 813.e7-813.e8.	1.7	4



#	ARTICLE	IF	CITATIONS
109	Interaction of Body Mass Index on the Association Between Nâ€Terminalâ€Proâ€Bâ€Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCENDâ€HF (Acute Study) Tj ETQq1 3.784314rgBT /Ov Association. 2018, 7, .	3.7	12
110	Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010â€2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. Journal of the American Heart Association, 2018, 7, .	3.7	17
111	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 525-532.	7.1	29
112	Is Time of the Essence? The Impact ofâTime of Hospital Presentation in AcuteâHeart Failure. JACC: Heart Failure, 2018, 6, 298-307.	4.1	4
113	Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart, 2018, 104, 1691-1698.	2.9	34
114	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. ESC Heart Failure, 2018, 5, 19-26.	3.1	10
115	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacyâand Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	4.1	141
116	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	3.3	27
117	Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review. Canadian Journal of Cardiology, 2018, 34, 168-179.	1.7	16
118	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 304-314.	7.1	42
119	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart, 2018, 5, e000908.	2.3	12
120	Effects of age, gender, and risk-factors for heart failure on native myocardial T1 and extracellular volume fraction using the SASHA sequence at 1.5T. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	3.4	0
121	Economic and Quality-of-Life Outcomes of Natriuretic Peptideâ€Guided Therapy for HeartâFailure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	2.8	20
122	Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis. Canadian Journal of Cardiology, 2018, 34, 1365-1368.	1.7	2
123	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004783.	2.2	13
124	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	2.0	39
125	Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography, 2018, 35, 1746-1754.	0.9	10
126	Oxygen therapy in acute myocardial infarctions: do we need to re-evaluate its necessity?. Expert Review of Cardiovascular Therapy, 2018, 16, 693-694.	1.5	1



#	ARTICLE	IF	CITATIONS
127	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
128	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	3.9	134
129	Examining the Influence of Component Outcomes on the Composite at the Design Stage. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004419.	2.2	1
130	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 1031-1038.	7.1	24
131	Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study. <i>American Heart Journal</i> , 2018, 202, 148-150.	2.7	17
132	Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF). <i>American Heart Journal</i> , 2018, 205, 87-96.	2.7	11
133	Reply to McClure et al. "Reader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2018, 34, 813.e3.	1.7	0
134	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	1.6	16
135	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
136	Effects of age, gender, and risk factors for heart failure on native myocardial T <sub>1</sub> and extracellular volume fraction using the SASHA sequence at 1.5T. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1307-1317.	3.4	9
137	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. <i>American Heart Journal</i> , 2018, 202, 84-88.	2.7	19
138	Composite End Points in Clinical Trials of Heart Failure Therapy. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
139	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017, 33, 166-169.	1.7	13
140	Diabetes and heart failure in the crosshairs: where is the target?. <i>European Journal of Heart Failure</i> , 2017, 19, 66-68.	7.1	0
141	Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women. <i>Canadian Journal of Cardiology</i> , 2017, 33, 911-917.	1.7	14
142	Identifying Low-Risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (<sc>PROACT</sc>) 3 and 4 Trials. <i>Academic Emergency Medicine</i> , 2017, 24, 691-700.	1.8	2
143	Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective" <i>Circulation</i> , 2017, 135, e889-e891.	1.6	4
144	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135.	2.7	5

#	ARTICLE	IF	CITATIONS
145	Navigating Choices Among a Sea of Comorbidities —. Journal of the American College of Cardiology, 2017, 69, 2380-2382.	2.8	0
146	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373.	2.2	102
147	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	4.1	11
148	Multitype Events and the Analysis of Heart Failure Readmissions. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	2
149	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039.	2.8	69
150	Dietary Self-management in Heart Failure: High Tech or High Touch?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 19.	0.9	5
151	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2017, 69, 712-744.	2.8	23
152	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. JACC: Heart Failure, 2017, 5, 1-13.	4.1	84
153	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e000022.	2.2	9
154	The Impact and Implications of Twitter for Cardiovascular Medicine. Journal of Cardiac Failure, 2017, 23, 266-267.	1.7	16
155	Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101 — Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017, 35, 870-877.	1.6	292
156	Subclinical Pulmonary Edema Is Associated With Reduced Exercise Capacity in HFpEF and HFrEF. Journal of the American College of Cardiology, 2017, 70, 1827-1828.	2.8	11
157	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	7.4	386
158	Ivabradine in Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	23
159	Letter by Kaul et al Regarding Article, “Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012”, Circulation, 2017, 136, 884-885.	1.6	0
160	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	1.7	503
161	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	1.7	28
162	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Heart Failure, 2017, 4, 301-311.	3.1	28

#	ARTICLE	IF	CITATIONS
163	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	7.1	53
164	Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 86.	6.1	1
165	Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. <i>International Journal of Cardiology</i> , 2017, 228, 558-562.	1.7	31
166	Power and Sample Size Estimation for Nonparametric Composite Endpoints: Practical Implementation using Data Simulations. <i>Journal of Modern Applied Statistical Methods</i> , 2017, 16, 215-230.	0.2	2
167	Cognitive decline in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 661-673.	3.9	57
168	Salt in the diet in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 196-203.	1.8	13
169	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	7.1	36
170	Insights into the importance of the electrocardiogram in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1032-1040.	7.1	22
171	Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 365-376.	2.2	7
172	Liver function tests in patients with acute heart failure and associated outcomes: insights from <scp>ASCEND-HF</scp>. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	7.1	45
173	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	7.1	14
174	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	13.7	229
175	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016, 4, E365-E370.	2.4	73
176	Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study. <i>Clinical Nutrition</i> ESPEN, 2016, 11, e26-e32.	1.2	24
177	The "obesity paradox"™ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Thromboembolic Events and Mortality in Atrial Fibrillation) Trial. <i>Journal of the American College of Cardiology</i> , 2016, 57, 2869-2878.	2.2	194
178	Heterogeneity across one disease, two drugs, three trials, and four guidelines: are we further ahead?. <i>European Journal of Heart Failure</i> , 2016, 18, 1244-1247.	7.1	0
179	Letter by McAlister and Ezekowitz Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure". <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	0
180	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	15

#	ARTICLE	IF	CITATIONS
181	Early Follow-Up After a Heart Failure Exacerbation. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	49
182	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. <i>JAMA Cardiology</i> , 2016, 1, 673.	6.1	81
183	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>BMJ Open</i> , 2016, 6, e010201.	1.9	11
184	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.6	26
185	Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 986.e1-986.e8.	1.7	9
186	Oxygen Therapy in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 783-790.	4.1	62
187	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	1.6	13
188	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	1.6	47
189	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	2.8	191
190	Coenzyme Q10 and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002639.	3.9	108
191	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	1.7	9
192	Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?. <i>American Heart Journal</i> , 2016, 175, 184-192.	2.7	31
193	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1356.e21-1356.e28.	1.7	9
194	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	1.7	13
195	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	1.7	86
196	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59
197	How to Do More With Less. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 460-462.	2.2	3
198	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	26

#	ARTICLE	IF	CITATIONS
199	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <sc>MAGGIC</sc> meta-analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	7.1	48
200	The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function. PLoS ONE, 2015, 10, e0138579.	2.5	12
201	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. PLoS ONE, 2015, 10, e0140607.	2.5	10
202	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2015, 170, 298-305.	2.7	38
203	Variation in Critical Care Unit Admission Rates and Outcomes for Patients With Acute Coronary Syndromes or Heart Failure Among High- and Low-Volume Cardiac Hospitals. Journal of the American Heart Association, 2015, 4, e001708.	3.7	42
204	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. Journal of the American Heart Association, 2015, 4, e002092.	3.7	25
205	The Effects of Climate Change on Cardiac Health. Cardiology, 2015, 131, 209-217.	1.4	1,123
206	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	1.7	96
207	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. American Heart Journal, 2015, 169, 122-131.e22.	2.7	24
208	Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. Journal of Applied Physiology, 2015, 118, 839-848.	2.5	15
209	Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. JACC: Heart Failure, 2015, 3, 193-201.	4.1	68
210	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <sc>ASCEND-HF</sc>. European Journal of Heart Failure, 2015, 17, 340-346.	7.1	22
211	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. International Journal of Cardiology, 2015, 182, 184-186.	1.7	2
212	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. American Heart Journal, 2015, 169, 743-750.	2.7	15
213	Reply. JACC: Heart Failure, 2015, 3, 271-272.	4.1	0
214	Assessing the Use of International Classification of Diseases-10th Revision Codes From the Emergency Department for the Identification of Acute Heart Failure. JACC: Heart Failure, 2015, 3, 386-391.	4.1	33
215	Diuretic response in acute heart failure—an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4.	2.7	110
216	Association Between Self-reported Adherence to a Low-Sodium Diet and Dietary Habits Related to Sodium Intake in Heart Failure Patients. Journal of Cardiovascular Nursing, 2015, 30, 58-65.	1.1	25

#	ARTICLE	IF	CITATIONS
217	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal, 2015, 170, 290-297.e1.	2.7	57
218	Estimates of Dietary Sodium Consumption in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2015, 21, 981-988.	1.7	16
219	Heart failure guidelines fail. Cmaj, 2015, 187, 912.2-912.	2.0	0
220	Re. "Dietary fatty acids intake and mortality in patients with heart failure" Authors' response. Nutrition, 2015, 31, 1185-1186.	2.4	0
221	The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): A pilot study. American Heart Journal, 2015, 169, 274-281.e1.	2.7	53
222	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions" A Consensus Document from the <sc>SAEM</sc>/<sc>HFSA</sc> Acute Heart Failure Working Group. Academic Emergency Medicine, 2015, 22, 94-112.	1.8	41
223	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	1.7	73
224	Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS ONE, 2015, 10, e0124844.	2.5	150
225	Heart Failure Re-Admission: Measuring the Ever Shortening Gap between Repeat Heart Failure Hospitalizations. PLoS ONE, 2014, 9, e106494.	2.5	33
226	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	3.9	42
227	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
228	Diabetes, impaired fasting glucose, and heart failure: Its not all about the sugar. European Journal of Heart Failure, 2014, 16, 1153-1156.	7.1	18
229	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 819-824.	1.7	9
230	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the <sc>ASCENDâ€HF T</sc>rial. European Journal of Heart Failure, 2014, 16, 334-341.	7.1	56
231	Time to Energize Coenzyme Q 10 for Patients With Heart Failure? â—. JACC: Heart Failure, 2014, 2, 650-652.	4.1	10
232	Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. BMC Cardiovascular Disorders, 2014, 14, 133.	1.7	20
233	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 259-268.	2.2	37
234	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders, 2014, 14, 91.	1.7	27



#	ARTICLE	IF	CITATIONS
235	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	1.7	57
236	Determinants of Early Readmission After Hospitalization for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 612-618.	1.7	40
237	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 267-273.e1.	2.7	13
238	Risk Stratification in Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 312-319.	1.7	39
239	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	1.7	44
240	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	1.7	14
241	Rates and reasons for device-based guideline eligibility in patients with heart failure. <i>Heart Rhythm</i> , 2014, 11, 1983-1990.	0.7	11
242	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	4.1	106
243	Trends in death attributed to myocardial infarction, heart failure and pulmonary embolism in Europe and Canada over the last decade. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 813-820.	0.5	21
244	Dietary fatty acids intake and mortality in patients with heart failure. <i>Nutrition</i> , 2014, 30, 1366-1371.	2.4	22
245	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). <i>Canadian Journal of Cardiology</i> , 2014, 30, 1208-1215.	1.7	11
246	Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. <i>American Heart Journal</i> , 2014, 168, 60-67.e5.	2.7	21
247	Mortality Outcomes Among Status Aboriginals and Whites With Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 619-626.	1.7	9
248	Optimizing Therapy of Heart Failure in the Aging Population with Monitoring in Clinics. , 2014, , 85-93.		0
249	Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. <i>International Journal of Biometeorology</i> , 2013, 57, 401-408.	3.0	8
250	Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure. <i>Current Cardiology Reports</i> , 2013, 15, 329.	2.9	4
251	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	2.8	78
252	Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials. <i>Current Heart Failure Reports</i> , 2013, 10, 373-379.	3.3	15



#	ARTICLE	IF	CITATIONS
253	Myocardial Deformation Analysis in Contrast Echocardiography: First Results Using Two-Dimensional Cardiac Performance Analysis. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1282-1289.	2.8	7
254	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
255	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 451-460.	3.9	136
256	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	1.7	176
257	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	4.1	22
258	Neither Diabetes nor Glucose-Lowering Drugs Are Associated With Mortality After Noncardiac Surgery in Patients With Coronary Artery Disease or Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 423-428.	1.7	9
259	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013, 168, 2315-2321.	1.7	13
260	Incidence of heart failure and mortality after acute coronary syndromes. <i>American Heart Journal</i> , 2013, 165, 379-385.e2.	2.7	80
261	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. <i>International Journal of Cardiology</i> , 2013, 168, 2127-2133.	1.7	34
262	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	1.7	53
263	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	2.8	191
264	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013, 34, 2464-2471.	2.2	154
265	Practice-Level Variation in Use of Recommended Medications Among Outpatients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1132-1138.	3.9	35
266	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 534-542.	2.2	25
267	The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*. <i>Critical Care Medicine</i> , 2013, 41, 2080-2087.	0.9	35
268	Changes in Heart Failure Outcomes After a Province-Wide Change in Health Service Provision A Natural Experiment in Alberta, Canada. <i>Circulation: Heart Failure</i> , 2013, 6, 76-82.	3.9	28
269	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	3.9	103
270	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. <i>Cmaj</i> , 2013, 185, E681-E689.	2.0	82

#	ARTICLE	IF	CITATIONS
271	Do Anticoagulants or Antiplatelet Drugs Have a Role in Treating Heart Failure in the Absence of Atrial Fibrillation?. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 435-438.	4.7	1
272	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure – OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). <i>Trials</i> , 2013, 14, 332.	1.6	5
273	Effect of low-dose dopamine on cardiorespiratory physiology in heart failure patients. <i>FASEB Journal</i> , 2013, 27, 928.6.	0.5	0
274	Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 735-741.	3.9	27
275	Response to Letter Regarding Article, “Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery: An Analysis of 38 047 Patients”. <i>Circulation</i> , 2012, 125, .	1.6	1
276	Testosterone Supplementation in Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 315-321.	3.9	166
277	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	3.9	152
278	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	2.2	652
279	Heart Failure Is a Clinically and Densitometrically Independent Risk Factor for Osteoporotic Fractures: Population-Based Cohort Study of 45,509 Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1179-1186.	3.6	50
280	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , 2012, 380, 1749-1758.	13.7	175
281	Heart failure: can we define, assess, and treat diastolic heart failure?. <i>European Journal of Heart Failure</i> , 2012, 14, 713-715.	7.1	3
282	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	1.7	93
283	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	1.7	50
284	Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. <i>American Heart Journal</i> , 2012, 164, 365-372.	2.7	139
285	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	2.8	35
286	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	2.8	3
287	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 106-113.	2.1	22
288	The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 299-307.	2.9	1

#	ARTICLE	IF	CITATIONS
289	Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. <i>European Journal of Heart Failure</i> , 2011, 13, 142-147.	7.1	116
290	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	27.0	1,133
291	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. <i>American Heart Journal</i> , 2011, 161, 986-992.e1.	2.7	38
292	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	1.7	139
293	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537
294	Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure. <i>Annals of Internal Medicine</i> , 2011, 154, 401.	3.9	113
295	Carotid chemoreceptor modulation of blood flow during exercise in healthy humans. <i>Journal of Physiology</i> , 2011, 589, 6219-6230.	2.9	47
296	Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women With Chronic Heart Failure?. <i>Congestive Heart Failure</i> , 2011, 17, 89-91.	2.0	23
297	The Correlation of Standard Heart Failure Assessment and Palliative Care Questionnaires in a Multidisciplinary Heart Failure Clinic. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 379-387.	1.2	38
298	Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. <i>BMC Cancer</i> , 2011, 11, 318.	2.6	76
299	Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. <i>European Journal of Heart Failure</i> , 2011, 13, 1211-1215.	7.1	8
300	Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. <i>Heart</i> , 2011, 97, 2046-2050.	2.9	73
301	The Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 419-424.	3.9	39
302	Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. <i>Evidence-Based Medicine</i> , 2011, 16, 138-139.	0.6	0
303	Ethnic differences in 1-year mortality among patients hospitalised with heart failure. <i>Heart</i> , 2011, 97, 1048-1053.	2.9	23
304	Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System. <i>Circulation: Heart Failure</i> , 2011, 4, 317-323.	3.9	95
305	Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery. <i>Circulation</i> , 2011, 124, 289-296.	1.6	186
306	Resource Use in the Last 6 Months of Life Among Patients With Heart Failure in Canada. <i>Archives of Internal Medicine</i> , 2011, 171, 211.	3.8	65

#	ARTICLE	IF	CITATIONS
307	The Prevalence of Natural Health Product Use in Patients with Acute Cardiovascular Disease. PLoS ONE, 2011, 6, e19623.	2.5	19
308	Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Critical Care Medicine, 2010, 38, 1793-1801.	0.9	17
309	The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews, 2010, 15, 407-413.	3.9	9
310	Association between obesity and health-related quality of life in patients with coronary artery disease. International Journal of Obesity, 2010, 34, 1434-1441.	3.4	43
311	A new pathway? Failure, fragility and fractures. European Heart Journal, 2010, 31, 9-11.	2.2	10
312	Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure. Mayo Clinic Proceedings, 2010, 85, 609-617.	3.0	135
313	Testosterone Therapy in Women With Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1317-1319.	2.8	7
314	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	1.7	1,086
315	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, 475-539.	1.7	267
316	Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2010, 16, 867-872.	1.7	26
317	Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. American Heart Journal, 2010, 159, 131-140.	2.7	19
318	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal, 2010, 160, 272-278.	2.7	29
319	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal, 2010, 160, 671-677.	2.7	18
320	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Canadian Journal of Cardiology, 2010, 26, 185-202.	1.7	125
321	A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case Reports in Medicine, 2009, 2009, 1-3.	0.7	19
322	A Call to Action: Cardiac Palliative Care. Journal of Palliative Medicine, 2009, 12, 289-290.	1.1	1
323	Response to Letter Regarding Article, "Heart Failure Is a Risk Factor for Orthopedic Fracture: A Population-Based Analysis of 16 294 Patients". Circulation, 2009, 120, .	1.6	0
324	What Price to Pay?. Circulation, 2009, 119, 368-370.	1.6	2

#	ARTICLE	IF	CITATIONS
325	Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. <i>European Heart Journal</i> , 2009, 30, 2213-2219.	2.2	4
326	The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. <i>European Heart Journal</i> , 2009, 30, 2584-2592.	2.2	121
327	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	2.7	36
328	Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 13-20.	2.8	309
329	Meta-analysis: $\beta$ -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. <i>Annals of Internal Medicine</i> , 2009, 150, 784.	3.9	426
330	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009, 25, 85-105.	1.7	79
331	Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. <i>Annals of Internal Medicine</i> , 2009, 150, JC5.	3.9	2
332	Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction $\geq 50\%$ Versus Those With Ejection Fraction $< 50\%$ . <i>American Journal of Cardiology</i> , 2008, 102, 79-83.	1.6	21
333	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008, 24, 21-40.	1.7	93
334	Heart Failure Is a Risk Factor for Orthopedic Fracture. <i>Circulation</i> , 2008, 118, 1946-1952.	1.6	136
335	Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. <i>European Heart Journal</i> , 2008, 30, 469-477.	2.2	145
336	Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 308-314.	7.1	104
337	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2502.	7.4	497
338	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 173-178.	1.4	10
339	Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction. <i>Annals of Internal Medicine</i> , 2007, 147, 251.	3.9	146
340	Anemia in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301.	2.8	13
341	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2006, 22, 393-397.	1.7	25
342	Proportion of Patients Followed in a Specialized Heart Failure Clinic Needing an Implantable Cardioverter Defibrillator as Determined by Applying Different Trial Eligibility Criteria. <i>American Journal of Cardiology</i> , 2006, 97, 882-885.	1.6	18

#	ARTICLE	IF	CITATIONS
343	Challenges in Systematic Reviews of Therapeutic Devices and Procedures. <i>Annals of Internal Medicine</i> , 2005, 142, 1100.	3.9	61
344	Impact of specialist follow-up in outpatients with congestive heart failure. <i>Cmaj</i> , 2005, 172, 189-194.	2.0	151
345	Time-dependent analysis in CHF follow-up. <i>Cmaj</i> , 2005, 173, 238-239.	2.0	0
346	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. <i>BMJ: British Medical Journal</i> , 2005, 331, 873.	2.3	67
347	The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. <i>Canadian Journal of Cardiology</i> , 2005, 21, 165-71.	1.7	20
348	The Use of $\beta$ -Blockers in a Tertiary Care Heart Failure Clinic. <i>Archives of Internal Medicine</i> , 2004, 164, 769.	3.8	43
349	Renal Insufficiency and Heart Failure. <i>Circulation</i> , 2004, 109, 1004-1009.	1.6	651
350	Usefulness of spironolactone in a specialized heart failure clinic. <i>American Journal of Cardiology</i> , 2004, 94, 443-447.	1.6	28
351	The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1587-1592.	2.8	331
352	Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 165-173.	1.7	19
353	Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. <i>Annals of Internal Medicine</i> , 2004, 141, 381.	3.9	274
354	Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes. <i>Circulation</i> , 2003, 107, 223-225.	1.6	789
355	Implantable Cardioverter Defibrillators in Primary and Secondary Prevention. <i>Annals of Internal Medicine</i> , 2003, 138, 445.	3.9	234
356	Defibrillators and Sudden Death. <i>Annals of Internal Medicine</i> , 2003, 139, W-85.	3.9	0
357	Stroke: strategies for primary prevention. <i>American Family Physician</i> , 2003, 68, 2379-86.	0.1	15
358	The waiting game: facing the consequences. <i>Cmaj</i> , 2002, 167, 1247-8.	2.0	1
359	Successful cryopreservation of rat islets using ethylene glycol. <i>Transplantation Proceedings</i> , 1997, 29, 1983.	0.6	3
360	CRYOPRESERVATION OF RAT PANCREATIC ISLETS. <i>Transplantation</i> , 1997, 64, 1065-1070.	1.0	23

#	ARTICLE	IF	CITATIONS
361	Surprise outcome for SODIUM-HF. , 0, , .		0